We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.34M
AUM Growth
+$152K
Cap. Flow
+$568K
Cap. Flow %
8.95%
Top 10 Hldgs %
97.4%
Holding
21
New
7
Increased
3
Reduced
1
Closed
10

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$1.26M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$713K
3
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$606K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$536K
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$460K

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$755K
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$710K
3
ABBV icon
AbbVie
ABBV
+$649K
4
RVMD icon
Revolution Medicines
RVMD
+$459K
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$355K

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Industrials 5.99%
3 Consumer Staples 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$120B
$1.81M 28.62%
9,000
+6,000
+200% +$1.26M
FATE icon
2
Fate Therapeutics
FATE
$294M
$868K 13.69%
10,000
+2,000
+25% +$161K
ATRA icon
3
Atara Biotherapeutics
ATRA
$73.6M
$778K 12.27%
+2,000
New +$713K
ZNTL icon
4
Zentalis Pharmaceuticals
ZNTL
$317M
$532K 8.39%
+10,000
New +$536K
TCRR
5
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$492K 7.76%
+30,000
New +$606K
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$468K 7.38%
+5,000
New +$460K
ACCD
7
DELISTED
Accolade Inc
ACCD
$380K 5.99%
+7,000
New +$340K
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$16B
$355K 5.6%
+2,000
New +$346K
GRTS
9
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$320K 5.05%
35,000
-2,000
-5% -$18.5K
SKIN icon
10
SkinHealth Systems
SKIN
$95.9M
$168K 2.65%
+10,000
New +$137K
RCUS icon
11
Arcus Biosciences
RCUS
$3.74B
$165K 2.6%
20,000
+10,000
+100% +$286K
ABBV icon
12
AbbVie
ABBV
$454B
– –
-6,000
Closed -$649K
ARDX icon
13
Ardelyx
ARDX
$1.27B
– –
-50,000
Closed -$331K
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.4B
– –
-10,000
Closed -$755K
RCKT icon
15
Rocket Pharmaceuticals
RCKT
$358M
– –
-8,000
Closed -$355K
REGN icon
16
Regeneron Pharmaceuticals
REGN
$68.3B
– –
-1,500
Closed -$710K
RVMD icon
17
Revolution Medicines
RVMD
$40.1B
– –
-10,000
Closed -$459K
TDOC icon
18
Teladoc Health
TDOC
$1.56B
– –
-1,500
Closed -$273K
TGTX icon
19
TG Therapeutics
TGTX
$8.5B
– –
-7,000
Closed -$337K
BCEL
20
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-18,000
Closed -$276K
ORTX
21
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-1,500
Closed -$109K

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Copernicus Capital Management held 21 positions worth $6.34M, up 2.5% from $6.19M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Copernicus Capital Management deployed $568K of net new capital in Q2 2021, opening 7 new positions and adding to 3 existing holdings. Its largest new stake was Atara Biotherapeutics: 2,000 shares worth $778K.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 100% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Gritstone bio, Inc. Common Stock, an estimated $18.5K trimmed.

  • Copernicus Capital Management's largest Q2 2021 buy was Atara Biotherapeutics: 2,000 shares worth $778K.
  • Copernicus Capital Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $1.26M increase.
  • Copernicus Capital Management's biggest Q2 2021 reduction was Gritstone bio, Inc. Common Stock, cutting an estimated $18.5K.
  • Copernicus Capital Management fully exited BioMarin Pharmaceuticals in Q2 2021, selling an estimated $755K.
  • Copernicus Capital Management's ten largest holdings make up 97% of its $6.34M portfolio in Q2 2021.
  • Copernicus Capital Management opened 7 new positions and closed 10 in Q2 2021.
  • Copernicus Capital Management's portfolio value rose 2.5% quarter-over-quarter to $6.34M.

Based on Copernicus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.